Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Fathi

Showing results (11-20 of 206) with videos related to

Pageof 21
Sort By:
The Oncologist|August 11, 2016
In ReplyAmir T Fathi, Andrew S Chi
Current Cancer Drug Targets|April 25, 2020
Targeting IDH Mutations in AML: Wielding the Double-edged Sword of DifferentiationJustin S Becker, Amir T Fathi
European Journal of Haematology|December 22, 2016
The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemiaAmir T Fathi, Yi-Bin Chen
Current Hematologic Malignancy Reports|March 20, 2014
Treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantationAmir T Fathi, Yi-Bin Chen
American Journal of Blood Research|March 21, 2012
Treatment of FLT3-ITD acute myeloid leukemiaAmir T Fathi, Yi-Bin Chen
Seminars in Thoracic and Cardiovascular Surgery|November 29, 2008
Chemotherapy for advanced stage non-small cell lung cancerAmir T Fathi, Julie R Brahmer
Current Oncology Reports|August 15, 2009
New agents in acute myeloid leukemia: beyond cytarabine and anthracyclinesAmir T Fathi, Judith E Karp
The Oncologist|July 19, 2011
FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulationsAmir T Fathi, Bruce A Chabner
Cancer|May 12, 2026
Defining a role for venetoclax and hypomethylating agent therapy in younger adults with acute myeloid leukemiaBrandon J Aubrey, Amir T Fathi
Advances in Hematology|August 4, 2011
Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapyAmir T Fathi, Omar Abdel-Wahab
Pageof 21

Showing results (11-20 of 206) with videos related to

Sort By:
Pageof 21
The Oncologist|August 11, 2016
In ReplyAmir T Fathi, Andrew S Chi
Current Cancer Drug Targets|April 25, 2020
Targeting IDH Mutations in AML: Wielding the Double-edged Sword of DifferentiationJustin S Becker, Amir T Fathi
European Journal of Haematology|December 22, 2016
The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemiaAmir T Fathi, Yi-Bin Chen
Current Hematologic Malignancy Reports|March 20, 2014
Treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantationAmir T Fathi, Yi-Bin Chen
American Journal of Blood Research|March 21, 2012
Treatment of FLT3-ITD acute myeloid leukemiaAmir T Fathi, Yi-Bin Chen
Seminars in Thoracic and Cardiovascular Surgery|November 29, 2008
Chemotherapy for advanced stage non-small cell lung cancerAmir T Fathi, Julie R Brahmer
Current Oncology Reports|August 15, 2009
New agents in acute myeloid leukemia: beyond cytarabine and anthracyclinesAmir T Fathi, Judith E Karp
The Oncologist|July 19, 2011
FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulationsAmir T Fathi, Bruce A Chabner
Cancer|May 12, 2026
Defining a role for venetoclax and hypomethylating agent therapy in younger adults with acute myeloid leukemiaBrandon J Aubrey, Amir T Fathi
Advances in Hematology|August 4, 2011
Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapyAmir T Fathi, Omar Abdel-Wahab
Pageof 21